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a b s t r a c t
Historically, oral mucositis (OM) has been identified as a symptom developing in patients
undergoing irradiation due to head and neck cancers, those undergoing therapy in pre-
paration for a stem cell transplant, or receiving special therapeutic protocols due to acute
myeloid leukaemia. It results from direct toxic injury to the mucosal epithelial cells by
the immunosuppressive regimen. In this article we want to describe pathogenesis, diag-
nostic and actual possibility of treatment of OM. The literature reports several rating
scale for OM that have been used for patients undergoing cancer therapy. The most
useful of them are Oral Toxicity Scale and Oral Mucositis Assessment Scale. In the pre-
vention and treatment of OM associated with standard chemotherapy various drugs and
agents acting locally and systemically are used. Many of them are still remaining in the
course of research.
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Haematopoietic stem cell transplantation (HSCT) involves
the intravenous infusion of allogeneic or autologous stem
cells collected from bone marrow, peripheral blood or
umbilical cord blood in patients whose bone marrow or
immune system has been damaged. After administered
them into the body, their objective is to re-establish* Corresponding author at: Klinika Chirurgii Szczękowo-Twarzowej U
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Urban & Partner Sp. z o.o. All rights reserved.haematopoietic function. In allogeneic transplant, a donor
of the same species is the source of cells, and in autologous
transplant, haematopoietic cells come from the recipient
himself or herself. There are also syngeneic transplants
(genetically identical twins). Indications for this therapeutic
treatment include primarily haematopoietic malignancies,
such as leukaemias, lymphomas, myelomas, myelodysplas-
tic syndromes, advanced lung, ovarian, breast, testicular
cancers, as well as benign diseases, such as aplasticM, ul. Karmelicka 7, 20-081 Lublin, Poland. Tel.: +48 81 532 38 51;
ów, Instytut Hematologii i Transfuzjologii. Published by Elsevier
Table II – Groups of anticancer drugs responsible for
mucositis
Thymidine synthetase inhibitors Methotrexate




Intercalating drugs Idarubicin, doxorubicin,
daunorubicin
Table I – Conditioning regimens in PBSCT
BEAM BCNU, etoposide, cytarabine, melphalan
BuMel Busulfan, melphalan in high doses
BorMel Botezomib, melphalan in high doses
Melphalan High doses 140–200 mg/m2
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prior to the HSCT, which involves administering high-dose
chemotherapy, often in combination with radiation therapy.
Such therapy leads to myeloablation and destruction not
only of cancer cells, but also of recipient's haematopoietic
system. Non-myeloablative transplants with reduced-inten-
sity conditioning are also used, which involve the applica-
tion of lower doses of chemotherapy in combination with
strong immunosuppressive treatment. Such therapy can be
used in older patients over 65 years of age on account of
lower toxicity. Negative effects of toxic conditioning therapy
include intensified inflammations of the mucous membrane
of the mouth, nasopharynx and intestines, so called muco-
sitis [1, 2]. Some groups of anticancer drugs which are used
alone or in combination, as chemotherapy before autologous
HSCT are particularly often responsible for mucositis. The
most recorded mucotoxic agents are: thymidine synthetase
inhibitors, such as methotrexate, topoisomerase II inhibitors
(etoposide, irinotecan); pyrmidine analogues (cytarabine);
purine analogues (6-mercaptopurine and 6-thioguanine);
alkylating agents at high doses (busulfan, melphalan and
cyclophosphamide); and intercalating drugs (idarubicin, dox-
orubicin, daunorubicin). When these agents are adminis-
tered in multiple cycles the risk of mucositis increases at
each course [3] (Tables I and II).
Pathomechanism and clinical symptoms of
mucositis
Inflammation of the mucous membrane lining the oral
cavity and other parts of the gastrointestinal tract and
nasopharynx is a serious complication of the above men-
tioned conditioning therapy, and affects 80–100% of patients
[4]. The course is often so severe that patients require strong
analgesics and parenteral nutrition [5]. In view of patients'Table III – The pathobiology of mucositis-five phases
Phase I Phase II Phase III 




















Apoptosis of basal epithelial
cells and mucosal damagesubjective opinions, it is also one of the most intolerable
side effects of the therapy. It is a pathological process
common for cancer patients receiving radiation therapy,
chemotherapy or both of these treatments, and patients
requiring autogenic stem cell transplantation. Mucosal inju-
ries affect the entire gastrointestinal tract, from oral cavity
to anus [6]. Resulting lesions occurring in epithelium and
tunica submucosa are characterised in five clinical phases:
(a) initiation, (b) primary damage response, (c) signal ampli-
fication, (d) ulceration, and (e) healing [7–10] (Tab. III).
Primary mucosal cell injuries resulting from oxidative
stress lead to the expression of early response genes and
activation of DNA transcription factor. The pathophysiology
of mucositis involves various factors, such as nuclear factor
kappa B (NF-kappa B) protein complex playing an essential
role in the immune response to an infectious agent,
cyclooxygenase-2 (COX-2) activated by agents related to the
inflammation, pro-inflammatory cytokines – in particular
interleukin (IL)-1b (IL)-6, and tumour necrosis factor (TNF)
[7, 8]. Clinically, it begins with non-specific oral discomfort
preceded by redness, burning sensation, increased sensitiv-
ity to sour and hot foods, then erosion and ulcers occur that
make it difficult to take and swallow foods, accompanied by
a series of other symptoms that make patient's functioning
difficult, of which the following should be listed: pain,
swelling, fever, mycosis, bacteraemia and sepsis [4, 6, 11,
12]. Then, viral infection symptoms dominate with
increased mucosal temperature on hard palate, gingive and
dorsum of tongue combined with necrosis and extensive
lichenoid lesions. Quantitative and qualitative salivary
changes leading to a decrease in salivary IgG, IgA, IgM levels
and to xerostomia add to it [6, 9, 12, 13]. As a consequencePhase IV Phase V
n Ulceration Healing












Fig. 1 – Clinical symptoms of mucositis
Table IV – WHO's Oral Toxicity Scale
Oral Toxicity Scale
Grade 1 Soreness  erythema
Grade 2 Erythema, ulcers; patient can swallow solid food
Grade 3 Ulcers with extensive erythema patient cannot
swallow food
Grade 4 Mucositis to the extent alimentation is not
possible
Table V – OMAS Oral Assessment Scale in mucositis
Oral Mucositis Assessment Scale (OMAS)
Erythema
08 No erythema
18 Mild to moderate erythema
28 Severe erythema
Ulceration
08 No clinical lesion
18 An ulcer <1 cm2
28 An ulcer of 1–3 cm2
38 An ulcer >3 cm2
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which are not present in normal flora in this area, e.g.
Gram-negative – Escherichia coli, Klebsiella pneumoniae, Enter-
obacter cloacae, Pseudomonas aeruginosa, Gram-positive: Strep-
tococcus mitis, Streptococcus oralis, Streptococcus sanguis,
capnophyles and fusobacteria, fungi of the genus Candida –
Candida albicans and Candida tropicalis, leading to multi-organ
systemic mycosis [12, 13]. Bacterial cell walls produce
lipopolysaccharides which stimulate macrophages to pro-
duce damaging cytokines (Fig. 1).
Diagnosis and estimate of changes
For the evaluation of OM, two scales to assess lesions within
the mucosa are used that have been developed by the World
Health Organisation: Oral Toxicity Scale and Oral Mucositis
Assessment Scale (OMAS). As regards the interpretation of
symbols applied in these scales, 0 represents no pathologic
lesions, 1 – erythema requiring no clinical treatment, 2 –
presence of pain requiring no analgesics and difficulty in
swallowing. In grade 3 – mucosal ulcers, pain requiring
painkillers (analgesics) are present, feeding is totally impos-
sible, and finally grade 4 – necrosis and necessity of
parenteral nutrition. For more detailed evaluation of lesions
in a form of erythema and ulceration, OMAS scale is used:
a severity of ulcerations is characterised by 3 groups. This
evaluation relates to vermilion on the right and on the left,
lip mucosa, jugal mucosa, palate, floor of the mouth, lateral
tongue surface on both sides, and dorsal surface of the
tongue (Tables IV and V).
The incidence and clinical severity of OM depend on
a type and a dose of irradiation, combination of radiation
therapy with the chemotherapy, a type and dose of
a chemotherapeutic. In the last case, high toxicity of
preparations such as 5-FU, cisplatin, etoposide, melphalan
was reported, and slightly lower toxicity in the case of drugs
such as: doxorubicin, vinblastine, taxan, methotrexate, and
finally very rare toxicity if asparaginase and carmustine
were administered [8, 9]. Combination therapy with several
chemotherapeutics increases the incidence of OM from 40%to 70% compared to standard chemotherapy. In those
patients who receive conditioning treatment prior to the
HSCT – in particular if it consists of TBI (ionising irradiation
– total body irradiation) in combination with chemotherapy
– the incidence of OM is 75–99% [9]. Other factors that are
not associated with a type of therapy also play a role in
etiopathogenesis, namely patient's age, gender, race, general
condition, systemic disease. The results from studies carried
out to investigate risk factors are inconclusive; however,
they suggest that oral inflammation affects more women
than men. People over the age of 50 years and children are
at higher risk of OM [9]. OM is more common in older people
due to the decreased effectiveness of regenerative and
immune system processes, and in children due to a greater
rate of basal epithelium cells' division [8, 9, 14].
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Apart from the general medical approach, dental manage-
ment is also an important aspect of comprehensive prepara-
tion of a patient both for auto- and allo-HSCT. It should be
carried out at least two months prior to the planned
transplant, and should include detailed intra- and extra-oral
examinations supported by examinations such as an Ortho-
pantomogram (OPG), X-rays of individual teeth of which the
state raises doubts, or an X-ray of the paranasal sinuses.
Not only teeth should be evaluated, but also oral mucosa,
parodontium, parotid glands and their orifices, namely all
measures should be taken to identify and eliminate poten-
tial foci of infection, and consequently, complications after
the transplant. All therapeutic procedures should be carried
out in consultation with a treating haematologist on the
basis of current blood test results. If invasive procedures are
planned, such as extractions of teeth, dental plaque removal
or endodontic treatment, local procedures should be supple-
mented with antibiotic prophylaxis. Teeth damaged due to
decay process requiring sophisticated and long-term endo-
dontic procedures, teeth following endodontic treatment if
root canals are filled carelessly or periapical lesions are
present, totally and partially retained teeth affected by
pathological processes in surrounding tissues now or in the
future, teeth affected by advanced paradentosis are qualified
for extraction [15].
There are no standards for the prevention and treatment
of OM [4]. All currently used measures are still investigated
in clinical studies. Certainly, daily oral care is extremely
important. For this purpose, tooth brushing 2–3 times a day
or after every meal using ultra-soft toothbrush, ideally
changed every day, are recommended in patients. Special
dental pastes with a peroxidase system (e.g. Biotene) should
be used. If the symptoms of xerostomia are present, this
system helps to restore protective function of saliva and to
prevent primary and secondary oral infections [8, 16, 17]. It
is inadvisable to use toothpicks and dental floss due to
additional soft tissue trauma [8]. Supplementary rinsing of
the mouth 3 times a day is recommended using solutions
with additives such as chlorhexidine and xylitol [17]. At the
Haematooncology and Bone Marrow Transplantation
Department of the Medical University of Lublin, it is used
in a concentration of 0.2%, in a preparation Corsodyl, in
combination with antifungal agent – amphotericin
B (Fungizone) as a suspension. Chlorhexidine is thought to
play a major role in regulating the amount of dental plaque,
reduces the risk of tooth decay and gingivitis, and prevents
fungal infections as well. It does not directly influence the
treatment of OM [9]. One of the first symptoms of OM is
very nagging pain. Local anaesthetics (diphenhydramine,
lidocaine, dyclonine) as well as nonsteroidal anti-inflamma-
tory drugs such as paracetamol are used in the manage-
ment of it. In severe mucositis when the pain is very strong,
opioids are given: morphine and derivatives and fentanyl,
with the route of administration tailored individually to the
needs of each patient (orally, intravenously, subcutaneously
or sublingually) [8, 18]. The local use of the preparation
called Caphosol is added to the above therapy. Caphosolmouth rinse contains calcium and phosphate ions, and
helps to maintain proper hygiene of the oral cavity, keep it
moist, and prevent oral mucositis (OM), if used regularly.
Caphosol can be used in combination with other treatment
options as it has no known interactions with other thera-
pies. The studies have shown its high efficacy in the
treatment of OM in patients receiving high-dose melphalan
[19].
New methods of therapy
At the University Hospital of the School of Medicine of
Ribeirao Preto, University of Sao Paulo (UHSMRP/USP),
mouthwash was developed called ‘‘Mucositis Formula’’. It is
used to treat the clinical symptoms of OM. ‘‘Mucositis
Formula’’ is a combination of anti-inflammatory (benzida-
mine) and antifungal (nystatin) substances, anaesthetics
(neututocain), and distilled water [5].
Pharmacological approaches to managing or alleviating
the symptoms of OM are well supported by physiotherapy
treatment, such as cryotherapy or laser treatment. The local
application of cold results in the constriction of blood
vessels, reduced flow of blood with high concentration of
cytostatic agents, and thus, lowers their mucotoxic action.
It has been proved that the use of cryotherapy in patients
treated with 5-fluorouracil decreases the risk of oral mucosa
inflammation by 50%. Such results can be obtained when
patients start to suck ice cubes 5 min before the administra-
tion of the drug, and continue to do so for the next 30 min
of the therapy period. The benefits accruing from such
approach are also observed in patients treated with high
doses of drugs such as melphalan, metotrexate, edatrexate,
etidronate, and in patients following the bone marrow
transplant [8, 9, 18].
The studies have also confirmed the positive impact of
helium–neon (He–Ne) laser in the prevention and treatment
of OM in HSCT patients. Low-power laser therapy acceler-
ates the epithelialization of lesions, decreases inflammation,
is effective in fighting the pain, and stimulates salivary
gland function [4, 17, 18].
A regards the prevention and treatment of mucositis,
many hopes are pinned upon cytokines as they influence the
course of inflammatory processes and immune response of
the body [18, 20]. Pro-inflammatory cytokines, including IL-1,
IL-2 as well as TNF, are thought to play a key role in the
pathogenesis of OM. Currently, granulocyte-colony stimulat-
ing factor (G-CSF) and granulocyte–monocyte colony stimulat-
ing factor (GM-CSF) are used for therapeutic purposes. G-CSF
is a glycoprotein that regulates the proliferation and differ-
entiation of haematopoietic cells by increasing the number
and stimulating the activity of neutrophils in peripheral
blood, which shortens the duration of infection and neutro-
penia in persons undergoing myeloablative therapy before
the autoHSCT [11]. There is no clinical evidence on the
efficacy of the local use of the above preparations [20].
However, GM-CSF-synonym: CSF2, GMCSF, MGC administered
by subcutaneous injection over 5–14 days during the che-
motherapy, in particular if 5-FU, cisplatin, cyclophosphamide,
doxorubicin and etoposide, methotrexate, vinblastine and
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mucosal inflammation [9]. The drug is discontinued after the
white blood cell count is increased up to 1.0  10 [8].
Keratinocyte growth factor (KGF) is an important sub-
stance used systemically for the prevention and treatment
of mucositis. Palifermin (Kepivance) is a human KGF pro-
duced in E. coli [18]. It influences the proliferation and
reduces the apoptosis of epithelial cells, stimulates kerati-
nocyte migration, and thus participates in the wound
healing process. Palifermin at a dose of 60 mg/kg per day is
recommended before the auto-HSCT. The drug should be
started 3 days before the planned conditioning regimen, and
continued for the subsequent 3 days following the trans-
plant [20].
For the prevention and treatment of accompanying
fungal infections, substances that reduce clinical symptoms
of candidiasis in the oral cavity and gastrointestinal tract
are used. These include nystatine, clotrimazole, amphoter-
icin B, fluconazole [18].
It is thought that the prophylaxis for bacterial infections
is extremely important in HSCT patients, as they are
a common cause of complications and treatment failures.
Suggested antibiotics include new-generation quinolones,
levofloxacin and ciprofloxacin. These drugs show high
activity and efficacy against Gram-positive bacteria and P.
aeruginosa, and are of particular importance in the fight
against infections in auto-HSCT patients [21]. Moreover,
intravenous b-lactam antibiotics – third-generation cepha-
losporin (Biotum), aminoglycoside antibiotics – amikacin
(Biodacyna), and fluoroquinolone chemotherapeitics – cipro-
flozacin (Ciprofloksacin Kabi) are administered to treat
infections at the Haemato-oncology and Bone Marrow
Transplantation Clinic of the Medical University of Lublin.
Gastrointestinal symptoms accompanying high-dose
therapy: nausea, vomiting, diarrhoea, require that the nutri-
tional protocol be developed to be used in extreme cases of
parenteral nutrition and in every case with antiemetic drugs
(Torekan).
Preventive treatment
‘‘In agreeing with the rule, that prevention is better than
cure’’, the comprehensive dental management should
include the prophylaxis in a broad sense. It covers oral
hygiene instructions, selecting appropriate dental pastes,
brushes and mouthwash solutions, and frequent preventive
exams. It is important to ensure long-term dental care on
a regular basis to a patient after the transplantation, to
make it possible to diagnose and prevent inflammation of
the oral cavity that causes immune system disorders.
Summary
In general, mucositis should be treated conservatively to
avoid further tissue irritation and damaging the remaining
cells from which the epithelium will regenerate [9]. The
effects of severe mucositis are so adverse, causing serious
discomfort, lengthened hospital stays, additional hospitalcost, and increased risk for infection and mortality. Further
establishment of a methodology for oral health care in HSCT
will be needed, and further research should focus on
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